AP2706A - Purine derivatives and their use as modulators of toll-like receptor 7 - Google Patents

Purine derivatives and their use as modulators of toll-like receptor 7

Info

Publication number
AP2706A
AP2706A AP2009005072A AP2009005072A AP2706A AP 2706 A AP2706 A AP 2706A AP 2009005072 A AP2009005072 A AP 2009005072A AP 2009005072 A AP2009005072 A AP 2009005072A AP 2706 A AP2706 A AP 2706A
Authority
AP
ARIPO
Prior art keywords
toll
modulators
receptor
purine derivatives
purine
Prior art date
Application number
AP2009005072A
Other languages
English (en)
Other versions
AP2009005072A0 (en
Inventor
Michael Graupe
Randall L Halcomb
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39789972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2706(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AP2009005072A0 publication Critical patent/AP2009005072A0/en
Application granted granted Critical
Publication of AP2706A publication Critical patent/AP2706A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2009005072A 2007-06-29 2008-06-26 Purine derivatives and their use as modulators of toll-like receptor 7 AP2706A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93772607P 2007-06-29 2007-06-29
US95971407P 2007-07-16 2007-07-16
PCT/US2008/007955 WO2009005687A1 (en) 2007-06-29 2008-06-26 Purine derivatives and their use as modulators of toll-like receptor 7

Publications (2)

Publication Number Publication Date
AP2009005072A0 AP2009005072A0 (en) 2009-12-31
AP2706A true AP2706A (en) 2013-07-29

Family

ID=39789972

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2009005072A AP2706A (en) 2007-06-29 2008-06-26 Purine derivatives and their use as modulators of toll-like receptor 7

Country Status (22)

Country Link
US (5) US7968544B2 (xx)
EP (1) EP2170888B1 (xx)
JP (2) JP5395068B2 (xx)
KR (1) KR101561710B1 (xx)
CN (1) CN101784548B (xx)
AP (1) AP2706A (xx)
AR (1) AR067182A1 (xx)
AU (1) AU2008271127C1 (xx)
BR (1) BRPI0813952A2 (xx)
CA (1) CA2691444C (xx)
CO (1) CO6251258A2 (xx)
EA (2) EA024359B1 (xx)
EC (1) ECSP109905A (xx)
ES (1) ES2541434T3 (xx)
IL (1) IL202622A (xx)
MX (1) MX2009013832A (xx)
NZ (1) NZ582090A (xx)
PL (1) PL2170888T3 (xx)
PT (1) PT2170888E (xx)
SI (1) SI2170888T1 (xx)
TW (1) TWI434849B (xx)
WO (1) WO2009005687A1 (xx)

Families Citing this family (267)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI392678B (zh) * 2004-03-26 2013-04-11 Dainippon Sumitomo Pharma Co ９-取代-８-氧基腺嘌呤化合物
US7879797B2 (en) 2005-05-02 2011-02-01 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
BRPI0611435A2 (pt) * 2005-05-04 2010-09-08 Pfizer Ltd derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos
AU2006275605B2 (en) 2005-08-01 2011-01-06 Merck Sharp & Dohme Corp. Macrocyclic peptides as HCV NS3 protease inhibitors
ES2577514T3 (es) 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
JPWO2007034817A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
WO2007142755A2 (en) * 2006-05-31 2007-12-13 The Regents Of The University Of California Purine analogs
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
WO2008004948A1 (en) * 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
JP5345941B2 (ja) 2006-10-24 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
CA2667146C (en) 2006-10-24 2016-01-19 Merck & Co., Inc. Hcv ns3 protease inhibitors
CA2667165A1 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
US20100099695A1 (en) 2006-10-27 2010-04-22 Liverton Nigel J HCV NS3 Protease Inhibitors
ES2444575T3 (es) 2006-10-27 2014-02-25 Merck Sharp & Dohme Corp. Inhibidores de la proteasa NS3 del VHC
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2010513450A (ja) 2006-12-20 2010-04-30 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス性インドール
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
EA019151B1 (ru) 2007-02-07 2014-01-30 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Конъюгаты синтетических агонистов tlr и их применение
PT2125792E (pt) * 2007-02-19 2011-03-01 Glaxosmithkline Llc Derivados de purina como imunomoduladores
WO2008114008A1 (en) * 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
EP2139894B1 (en) * 2007-03-19 2011-10-26 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
EP2138497A4 (en) 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
AR065784A1 (es) * 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
JP5400763B2 (ja) * 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
ES2541434T3 (es) * 2007-06-29 2015-07-20 Gilead Sciences, Inc. Derivados de purina y su uso como moduladores del receptor de tipo Toll 7
CN101754970B (zh) 2007-07-17 2013-07-10 P.安杰莱蒂分子生物学研究所 用于治疗丙型肝炎的大环吲哚衍生物
WO2009010804A1 (en) 2007-07-19 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic compounds as antiviral agents
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
JPWO2009091031A1 (ja) * 2008-01-17 2011-05-26 大日本住友製薬株式会社 アデニン化合物の製造方法
CN102143964A (zh) * 2008-01-17 2011-08-03 大日本住友制药株式会社 制备腺嘌呤化合物的方法
EP2259788A4 (en) * 2008-02-07 2011-03-16 Univ California TREATMENT OF BLADDER DISEASES WITH A TLR7 ACTIVATOR
US8461107B2 (en) 2008-04-28 2013-06-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
SI2310095T1 (sl) 2008-07-22 2013-01-31 Merck Sharp & Dohme Corp. Makrocikliäśne kuinoksalinske spojine kot hcv ns3 proteazni inhibitorji
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
EA026557B1 (ru) 2008-12-09 2017-04-28 Джилид Сайэнс, Инк. Промежуточные соединения для получения модуляторов толл-подобных рецепторов
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
EP2923734B1 (en) 2009-03-13 2018-01-10 Katholieke Universiteit Leuven, K.U. Leuven R&D Purine analogues and their use as immunosuppressive agents
AR077139A1 (es) * 2009-06-23 2011-08-03 Gilead Sciences Inc Composiciones farmaceuticas utiles para tratar el vch
AR077138A1 (es) * 2009-06-23 2011-08-03 Gilead Sciences Inc Composiciones farmaceuticas utiles para tratar el vhc
PE20120493A1 (es) 2009-06-29 2012-05-20 Incyte Corp Pirimidinonas como inhibidores de pi3k
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
CA2772253C (en) * 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
US8507507B2 (en) * 2009-10-22 2013-08-13 Gilead Sciences, Inc. Modulators of toll-like receptors
EP2507237A1 (en) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
WO2011094489A1 (en) * 2010-01-29 2011-08-04 Vertex Pharmaceuticals Incorporated Therapies for treating hepatitis c virus infection
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
CA2797315C (en) 2010-04-30 2018-09-11 Telormedix Sa Phospholipid drug analogs
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
WO2012080728A1 (en) 2010-12-16 2012-06-21 Astrazeneca Ab Imidazo [4, 5 -c] quinolin- 1 -yl derivative useful in therapy
US8895570B2 (en) 2010-12-17 2014-11-25 Astrazeneca Ab Purine derivatives
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
TW201306841A (zh) 2010-12-20 2013-02-16 Gilead Sciences Inc 治療ｃ型肝炎病毒（ｈｃｖ）之方法
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
JP2014510743A (ja) * 2011-03-31 2014-05-01 シェファー、コンスタンツェ 核酸の非ウイルスの導入のためのパーフルオロ化化合物
EA027792B1 (ru) 2011-04-08 2017-09-29 Янссен Сайенсиз Айрлэнд Юси Производные пиримидина для лечения вирусных инфекций
JP2014520874A (ja) 2011-07-22 2014-08-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組成物
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
KR20230038593A (ko) 2011-09-02 2023-03-20 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
DE102011116417A1 (de) 2011-10-18 2013-04-18 Kurt Lucas Zimtrindenextrakt zur Behandlung von Erkrankungen infolge von induzierten Fehlsteuerungen des angeborenen Immunsystems
CN104066733A (zh) * 2011-11-09 2014-09-24 爱尔兰詹森研发公司 用于治疗病毒感染的嘌呤衍生物
JP2015504881A (ja) * 2011-12-20 2015-02-16 ギリアード サイエンシーズ， インコーポレイテッド 胃腸感染および障害を処置するための医薬組成物および方法
CA2862755A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
SG11201408542VA (en) * 2012-07-13 2015-02-27 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
EP2882721B1 (en) 2012-08-10 2018-12-05 Janssen Sciences Ireland Unlimited Company Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PE20150730A1 (es) 2012-08-24 2015-06-02 Glaxosmithkline Llc Compuestos de pirazolopirimidina
KR102280595B1 (ko) 2012-10-10 2021-07-22 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 다른 질환 치료를 위한 피롤로[3,2-d]피리미딘 유도체
CN111375056B (zh) 2012-10-10 2023-06-27 深圳大学 免疫受体调节剂偶联体及其制备方法和应用、制备其的偶联前体以及合成偶联前体的化合物
CN105051018B (zh) 2012-11-16 2019-09-20 爱尔兰詹森科学公司 用于治疗病毒性感染的杂环的经取代的2-氨基-喹唑啉衍生物
WO2014081645A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
CA2890201A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
AU2013348216B2 (en) 2012-11-20 2016-10-13 Glaxosmithkline Llc Novel compounds
UA118256C2 (uk) 2013-01-31 2018-12-26 Гіліад Фармассет Елелсі Комбінований склад двох противірусних сполук
CN105189468B (zh) 2013-02-21 2018-10-30 爱尔兰詹森科学公司 用于治疗病毒性感染的2-氨基嘧啶衍生物
MX366481B (es) * 2013-03-29 2019-07-09 Janssen Sciences Ireland Uc Deaza-purinonas macrociclicas para el tratamiento de infecciones virales.
DK3004074T3 (da) 2013-05-24 2018-01-29 Janssen Sciences Ireland Uc Pyridonderivater til behandling af virusinfektioner og yderligere sygdomme
NO3030563T3 (xx) 2013-06-27 2018-01-06
MX368625B (es) 2013-07-30 2019-10-08 Janssen Sciences Ireland Uc Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales.
KR102139847B1 (ko) * 2014-05-01 2020-07-31 노파르티스 아게 톨-유사 수용체 7 효능제로서의 화합물 및 조성물
CN106459058B (zh) 2014-05-01 2019-07-05 诺华股份有限公司 作为toll-样受体7激动剂的化合物和组合物
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
PT3166607T (pt) * 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
CN110759916B (zh) * 2014-08-15 2021-02-19 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
AU2015318061B2 (en) 2014-09-16 2018-05-17 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
PH12017501538B1 (en) 2015-02-27 2024-02-14 Incyte Holdings Corp Salts of p13k inhibitor and processes for their preparation
KR102394917B1 (ko) 2015-03-04 2022-05-09 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
WO2016177833A1 (en) 2015-05-04 2016-11-10 Bionor Immuno As Dosage regimen for hiv vaccine
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
JP2018525412A (ja) 2015-08-26 2018-09-06 ギリアード サイエンシーズ， インコーポレイテッド 重水素化トール様受容体調節因子
CR20180321A (es) 2015-12-15 2018-08-21 Gilead Sciences Inc Anticuerpos neutralizadores del virus de inmunodeficiencia humana
WO2017106556A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CA3021947A1 (en) * 2016-04-26 2017-11-02 Sumitomo Dainippon Pharma Co., Ltd. Substituted purine derivative
EP3452038B1 (en) 2016-05-05 2022-07-06 Laurus Labs Limited Process for the preparation of intermediates useful in the preparation of hepatitis c virus (hcv) inhibitors
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
MX2018014377A (es) 2016-05-27 2019-03-14 Gilead Sciences Inc Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
CA3027471A1 (en) 2016-07-01 2018-01-04 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
AU2017320742B2 (en) * 2016-08-29 2021-08-05 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
PT3507276T (pt) 2016-09-02 2022-01-11 Gilead Sciences Inc Compostos moduladores do recetor de tipo toll
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CN109790154B (zh) 2016-09-29 2023-06-23 爱尔兰詹森科学公司 用于治疗病毒感染和另外的疾病的嘧啶前药
MA46535A (fr) 2016-10-14 2019-08-21 Prec Biosciences Inc Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
US11084818B2 (en) 2016-11-11 2021-08-10 Hepo Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use
TWI714820B (zh) 2017-01-31 2021-01-01 美商基利科學股份有限公司 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
FI3603619T3 (fi) 2017-03-29 2025-09-25 Sumitomo Pharma Co Ltd Rokoteadjuvanttiformulaatio
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
US10457681B2 (en) * 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
JP6934562B2 (ja) 2017-08-22 2021-09-15 ギリアード サイエンシーズ， インコーポレイテッド 治療用複素環式化合物
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
JP2021035910A (ja) * 2017-11-01 2021-03-04 大日本住友製薬株式会社 置換プリン化合物
RS66222B1 (sr) 2017-12-07 2024-12-31 Univ Emory N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim
WO2019118884A1 (en) 2017-12-15 2019-06-20 Silverback Therapeutics, Inc. Antibody construct-drug conjugate for the treatment of hepatitis
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US12226480B2 (en) 2017-12-21 2025-02-18 Sumitomo Pharma Co., Ltd. Combination drug including TLR7 agonist
CN111699187A (zh) * 2018-02-12 2020-09-22 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的砜化合物和衍生物
SI3752501T1 (sl) 2018-02-13 2023-08-31 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
CN112469418A (zh) 2018-06-01 2021-03-09 因赛特公司 治疗pi3k相关病症的给药方案
US11168130B2 (en) 2018-07-03 2021-11-09 Gilead Sciences, Inc. Antibodies that target HIV GP120 and methods of use
WO2020010223A1 (en) 2018-07-06 2020-01-09 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
EP3818052A1 (en) 2018-07-06 2021-05-12 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
PH12021550175A1 (en) 2018-07-23 2022-07-11 Japan As Represented By Director General Of Nat Institute Of Infectious Diseases Composition containing influenza vaccine
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
JP2022500414A (ja) 2018-09-12 2022-01-04 シルバーバック セラピューティックス インコーポレイテッド 免疫刺激性コンジュゲートにより疾患を処置する方法および組成物
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
TWI721624B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
CA3117556A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
JP7350871B2 (ja) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ２’３’－環状ジヌクレオチドおよびそのプロドラッグ
HUE059677T2 (hu) 2019-03-22 2022-12-28 Gilead Sciences Inc Áthidalt triciklusos karbamoilpiridon-vegyületek és ezek gyógyszerészeti alkalmazása
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI762925B (zh) 2019-05-21 2022-05-01 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CA3140708A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
US20220249685A1 (en) 2019-06-19 2022-08-11 Silverback Therapeutics, Inc. Anti-mesothelin antibodies and immunoconjugates thereof
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
MY208114A (en) 2019-09-30 2025-04-16 Gilead Sciences Inc Hbv vaccines and methods treating hbv
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
US11795223B2 (en) 2019-10-18 2023-10-24 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CN116057068A (zh) 2019-12-06 2023-05-02 精密生物科学公司 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
US20230140430A1 (en) 2020-01-27 2023-05-04 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US12485123B2 (en) 2020-01-27 2025-12-02 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists
EP4097102A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
KR20220132601A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
KR20220132602A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
JP2023512230A (ja) 2020-01-27 2023-03-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしてのＣ３置換１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
KR20220132592A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
CN115210235A (zh) 2020-01-27 2022-10-18 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
CN115151548A (zh) 2020-01-27 2022-10-04 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
TWI832035B (zh) 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
EP4143194A1 (en) 2020-05-01 2023-03-08 Gilead Sciences, Inc. Cd73 inhibiting 2,4-dioxopyrimidine compounds
BR112022022409A2 (pt) 2020-05-06 2023-02-07 Ajax Therapeutics Inc 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2
EP4153181A1 (en) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
CN116209678A (zh) 2020-07-01 2023-06-02 安尔士制药公司 抗asgr1抗体缀合物及其用途
BR112023002164A2 (pt) 2020-08-07 2023-03-14 Gilead Sciences Inc Profármacos de análogos de nucleotídeos de fosfonamida e seu uso farmacêutico
EP4219504A4 (en) * 2020-09-27 2024-10-16 Shanghai Visonpharma Co., Ltd. MACROCYCLIC TLR7 AGONIST, MANUFACTURING METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CA3195799A1 (en) 2020-11-11 2022-05-19 Stephen R. Martin Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN114805341B (zh) * 2021-01-28 2023-12-08 上海翊石医药科技有限公司 一类芳杂环类化合物及其制备方法和用途
TW202304524A (zh) 2021-04-10 2023-02-01 美商普方生物製藥美國公司 Folr1結合劑、其結合物及使用方法
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
AU2022262644A1 (en) 2021-04-23 2023-11-09 Genmab A/S Anti-cd70 antibodies, conjugates thereof and methods of using the same
TW202348237A (zh) 2021-05-13 2023-12-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
CA3234909A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
JP2024541979A (ja) 2021-10-29 2024-11-13 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
EP4440702B1 (en) 2021-12-03 2025-05-21 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
JP7736929B2 (ja) 2021-12-03 2025-09-09 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症のための治療化合物
US12084467B2 (en) 2021-12-03 2024-09-10 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
KR20240125012A (ko) 2021-12-22 2024-08-19 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
DK4245756T3 (da) 2022-03-17 2024-10-21 Gilead Sciences Inc Ikaros zinkfinger-familiens nedbrydere og anvendelse heraf
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
IL316058A (en) 2022-04-21 2024-11-01 Gilead Sciences Inc Compounds modulate KRAS G12D
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
CR20240570A (es) 2022-07-01 2025-03-03 Gilead Sciences Inc Compuestos de cd73
AU2023307100A1 (en) 2022-07-12 2025-01-02 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
US20240083984A1 (en) 2022-08-26 2024-03-14 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
US20240226130A1 (en) 2022-10-04 2024-07-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
KR20250122479A (ko) 2022-12-22 2025-08-13 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
US20240383922A1 (en) 2023-04-11 2024-11-21 Gilead Sciences, Inc. KRAS Modulating Compounds
AR132464A1 (es) 2023-04-19 2025-07-02 Gilead Sciences Inc Régimen de dosificación de inhibidor de la cápside
AU2024259556A1 (en) 2023-04-21 2025-10-23 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024249573A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Solid forms of compounds useful in the treatment of hiv
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於ｈｉｖ之治療性化合物
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
US20250100998A1 (en) 2023-07-26 2025-03-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025072406A1 (en) 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
TW202530226A (zh) 2023-10-11 2025-08-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2025080863A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20250333424A1 (en) 2024-03-01 2025-10-30 Gilead Sciences, Inc. Antiviral compounds
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060052403A1 (en) * 2002-09-27 2006-03-09 Yoshiaki Isobe Novel adenine compound and use thereof
WO2007034817A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
WO2007034917A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2311742C (en) * 1997-11-28 2009-06-16 Sumitomo Pharmaceuticals Co., Ltd. 6-amino-9-benzyl-8-hydroxypurine derivatives
PT1040108E (pt) 1997-12-19 2004-06-30 Schering Ag Derivados de orto-antranilamida como anticoagulantes
TW572758B (en) * 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
JP2005089334A (ja) 2003-09-12 2005-04-07 Sumitomo Pharmaceut Co Ltd ８−ヒドロキシアデニン化合物
WO2005067901A2 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
TWI392678B (zh) * 2004-03-26 2013-04-11 Dainippon Sumitomo Pharma Co ９-取代-８-氧基腺嘌呤化合物
EP1750714A1 (en) 2004-05-13 2007-02-14 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
JP2008500338A (ja) 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
CN101123968A (zh) 2004-06-04 2008-02-13 艾科斯有限公司 肥大细胞病的治疗方法
EP1885356A2 (en) 2005-02-17 2008-02-13 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
BRPI0611435A2 (pt) * 2005-05-04 2010-09-08 Pfizer Ltd derivados de 2-amido-6-amino-8-oxopurina, composições farmacêuticas, uso e processo de preparo dos mesmos
ES2577514T3 (es) 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
TW200745114A (en) * 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
US20090099216A1 (en) * 2005-09-22 2009-04-16 Astrazeneca Aktiebolag A Corporation Of Sweden Novel adenine compound
EP1939198A4 (en) * 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
JPWO2007034882A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
JP2009519040A (ja) 2005-12-12 2009-05-14 エラン・フアーマシユーチカルズ・インコーポレーテツド パーキンソン病治療のためのアッセイおよびそこにおいて有用な酵素的に活性のあるＰａｒｋｉｎ調製物
WO2007142755A2 (en) 2006-05-31 2007-12-13 The Regents Of The University Of California Purine analogs
WO2008004948A1 (en) * 2006-07-05 2008-01-10 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of tlr7
AU2007269557B2 (en) * 2006-07-07 2013-11-07 Gilead Sciences, Inc. Modulators of toll-like receptor 7
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
PT2125792E (pt) * 2007-02-19 2011-03-01 Glaxosmithkline Llc Derivados de purina como imunomoduladores
WO2008114008A1 (en) * 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
EP2139894B1 (en) * 2007-03-19 2011-10-26 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators
AR065784A1 (es) * 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
EP2138497A4 (en) * 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
JP5400763B2 (ja) * 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
ES2541434T3 (es) * 2007-06-29 2015-07-20 Gilead Sciences, Inc. Derivados de purina y su uso como moduladores del receptor de tipo Toll 7
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
UA103195C2 (uk) * 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
EP2326646B1 (en) * 2008-08-11 2013-07-31 GlaxoSmithKline LLC Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
EP2320905B1 (en) * 2008-08-11 2017-06-28 Glaxosmithkline LLC Novel adenine derivatives
MX2011001662A (es) * 2008-08-11 2011-03-24 Glaxosmithkline Llc Derivados de purina para usarse en el tratamiento de enfermedades alergicas, inflamatorias e infecciosas.
WO2010018132A1 (en) * 2008-08-11 2010-02-18 Smithkline Beecham Corporation Compounds
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060052403A1 (en) * 2002-09-27 2006-03-09 Yoshiaki Isobe Novel adenine compound and use thereof
WO2007034817A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
WO2007034917A1 (ja) * 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物

Also Published As

Publication number Publication date
BRPI0813952A2 (pt) 2017-05-09
JP2014005308A (ja) 2014-01-16
AP2009005072A0 (en) 2009-12-31
CA2691444C (en) 2016-06-14
TWI434849B (zh) 2014-04-21
TW200914454A (en) 2009-04-01
AU2008271127B2 (en) 2013-12-05
JP5395068B2 (ja) 2014-01-22
KR101561710B1 (ko) 2015-10-19
CA2691444A1 (en) 2009-01-08
PL2170888T3 (pl) 2015-09-30
US20120244121A1 (en) 2012-09-27
IL202622A0 (en) 2010-06-30
IL202622A (en) 2016-12-29
EA024359B1 (ru) 2016-09-30
US20150239888A1 (en) 2015-08-27
WO2009005687A1 (en) 2009-01-08
HK1143145A1 (en) 2010-12-24
CN101784548B (zh) 2013-07-17
US8993755B2 (en) 2015-03-31
US20140135492A1 (en) 2014-05-15
CN101784548A (zh) 2010-07-21
AU2008271127C1 (en) 2014-04-17
JP2010532353A (ja) 2010-10-07
US20090047249A1 (en) 2009-02-19
CO6251258A2 (es) 2011-02-21
SI2170888T1 (sl) 2015-10-30
US9611268B2 (en) 2017-04-04
US7968544B2 (en) 2011-06-28
EA021463B1 (ru) 2015-06-30
ES2541434T3 (es) 2015-07-20
AR067182A1 (es) 2009-09-30
KR20100039368A (ko) 2010-04-15
AU2008271127A1 (en) 2009-01-08
EP2170888A1 (en) 2010-04-07
EA200971081A1 (ru) 2010-10-29
PT2170888E (pt) 2015-08-21
US20110236348A1 (en) 2011-09-29
ECSP109905A (es) 2010-04-30
MX2009013832A (es) 2010-03-10
EP2170888B1 (en) 2015-04-22
EA201490489A1 (ru) 2014-07-30
NZ582090A (en) 2012-05-25

Similar Documents

Publication Publication Date Title
AP2706A (en) Purine derivatives and their use as modulators of toll-like receptor 7
PL2038290T3 (pl) Modulatory receptora Toll-podobnego 7
EP2313111A4 (en) GREAT RECEPTOR AGONIST FORMULATIONS AND THEIR USE
IL211802A0 (en) Nmda receptor modulators and uses thereof
ZA201001051B (en) Benzylbenzene derivatives and methods of use
ZA200903495B (en) Substituted pyrimidines and their use as JNK Modulators
AP2455A (en) Tricyclic compounds and their use as glucocorticoid receptor modulators
IL202754A0 (en) Polycyclic guanine derivatives and use thereof
IL193173A0 (en) 3-deazapurine derivatives as tlr7 modulators
IL205947A0 (en) Phosphonic acid derivatives and their use as p2y12 receptor antagonists
ZA201000354B (en) Dual modulators of 5-HT2A and D3 receptors
ZA200903574B (en) 2-Phenyl-6-Aminocarbonyl-Pyrimidine derivatives and their use as P2Y12 Receptor antagonists
ZA200806811B (en) 3-Deazapurine derivatives as TLR7 Modulators
EP2155889A4 (en) TOLL RECEPTOR 3 MODULATORS AND USES THEREOF
ZA200904939B (en) Extended release formulation of nevirapine
IL200044A0 (en) Tricyclic compounds and their use as glucocorticoid receptor modulators
IL198402A0 (en) Allosteric modulators of the a1 adenosine receptor
EP2511281A4 (en) ACYCLIC PHOSPHONATE NUCLEOSIDE DERIVATIVE AND MEDICAL USE THEREOF
GB0703514D0 (en) Use of riboflavin
ZA201000661B (en) Purine derivatives and their use as modulators of toll-like receptor 7
GB0717955D0 (en) Preparation of modified nucleosides
HK1140207A (en) Polycyclic guanine derivatives and use thereof
GB0807710D0 (en) Receptor and modulators thereof
GB0705204D0 (en) Uses of (S)-clenbuterol